Aurinia Pharmaceuticals News

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference

Business WireMay 7 18:00

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 4 01:02

RBC Capital Gives a Buy Rating to Aurinia Pharmaceuticals (AUPH)

TipRanksMay 3 18:41

Aurinia Pharmaceuticals' LUPKYNIS: A Strong Buy on Surging Sales and Positive Market Indicators

TipRanksMay 3 18:36

Earnings Call Summary | Aurinia Pharmaceuticals(AUPH.US) Q1 2024 Earnings Conference

The following is a summary of the Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call Transcript:Financial Performance:Aurinia reported Q1 net revenue of $50.3 million, marking a 46% YoY growth.

Futu NewsMay 3 02:48 · Conference Call

Aurinia Pharmaceuticals Sees Robust Growth in 2024

TipRanksMay 2 18:38

Aurinia Pharmaceuticals (AUPH.US): The 2024 Q1 financial report achieved revenue of $50.303 million, previous value of US$344.09 million, expected value of US$47.45 million; earnings per share were -0.07 USD, previous value of -0.18 USD, and expected valu

Aurinia Pharmaceuticals (AUPH.US): The 2024 Q1 financial report achieved revenue of $50.303 million, previous value of US$344.09 million, expected value of US$47.45 million; earnings per share were -0.07 USD, previous value of -0.18 USD, and expected value of -0.14 USD.

Zhitong FinanceMay 2 18:31

Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, Vs. Street Est of $47.1M

06:12 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M

MT NewswiresMay 2 18:12

Aurinia Pharmaceuticals 1Q Loss/Shr 7c >AUPH

Aurinia Pharmaceuticals 1Q Loss/Shr 7c >AUPH

Dow JonesMay 2 18:04

Aurinia Pharmaceuticals Maintains Established Net Pdt Rev Guidance for a Range of $200M to $220M >AUPH

Aurinia Pharmaceuticals Maintains Established Net Pdt Rev Guidance for a Range of $200M to $220M >AUPH

Dow JonesMay 2 18:04

Aurinia Reiterates 2024 Net Product Revenue Guidance Of $200M-$220M

Aurinia Reiterates 2024 Net Product Revenue Guidance Of $200M-$220M

BenzingaMay 2 18:03

Press Release: Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results -- Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first qu

Dow JonesMay 2 18:00

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results May 2, 2024 • 6:00 am EDT Download as PDF Related Documents E

Aurinia PharmaceuticalsMay 2 18:00

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)

TipRanksMay 2 14:22

Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)

TipRanksMay 2 14:20

Aurinia Pharmaceuticals Announced Several Initiatives To Improve Understanding Of The Seriousness Of Lupus Nephritis And The Need For Frequent Screening And Appropriate Management

Aurinia Pharmaceuticals Announced Several Initiatives To Improve Understanding Of The Seriousness Of Lupus Nephritis And The Need For Frequent Screening And Appropriate Management

BenzingaMay 1 18:19

Aurinia Underscores Enduring Commitment to People Living With Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month

In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and

BusinesswireMay 1 18:00

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS (Voclosporin) Label to Include Long-Term Data From the AURORA Clinical Program

New data showing sustained complete renal response with LUPKYNIS through three years Monthly kidney function assessment no longer required after first year of treatment Safety profile remains unchanged and is

BusinesswireApr 30 18:00

Aurinia Pharmaceuticals to Present at Investor Conference

TipRanksApr 16 23:38

UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference

NOTE: The new presentation time for Aurinia's presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conferences is 4:00 to 4:30 PM Eastern Time. This event is presentation only. Webcast Details remain the

BusinesswireApr 16 22:48